相似文献
1
The delta-opioid receptor and Parkinson's disease.
CNS Neurosci Ther. 2018 Dec;24(12):1089-1099. doi: 10.1111/cns.13045. Epub 2018 Aug 3.
2
Neuromodulation in Parkinson's disease targeting opioid and cannabinoid receptors, understanding the role of NLRP3 pathway: a novel therapeutic approach.
Inflammopharmacology. 2023 Aug;31(4):1605-1627. doi: 10.1007/s10787-023-01259-0. Epub 2023 Jun 15.
3
A zebrafish screen reveals Renin-angiotensin system inhibitors as neuroprotective via mitochondrial restoration in dopamine neurons.
Elife. 2021 Sep 22;10:e69795. doi: 10.7554/eLife.69795.
4
Glutamate receptors as therapeutic targets for Parkinson's disease.
CNS Neurol Disord Drug Targets. 2009 Dec;8(6):475-91. doi: 10.2174/187152709789824606.
5
Drugs used to treat Parkinson's disease, present status and future directions.
CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42. doi: 10.2174/187152708786441867.
6
[Coenzyme Q10 in Parkinson's disease. Symptomatic or neuroprotective effects?].
Nervenarzt. 2007 Dec;78(12):1378-82. doi: 10.1007/s00115-007-2285-1.
7
Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
Brain. 2013 Aug;136(Pt 8):2369-78. doi: 10.1093/brain/awt196.
8
Glutamate receptors and Parkinson's disease: opportunities for intervention.
Drugs Aging. 2003;20(5):377-97. doi: 10.2165/00002512-200320050-00006.
9
Biomarkers of Parkinson's disease: present and future.
Metabolism. 2015 Mar;64(3 Suppl 1):S40-6. doi: 10.1016/j.metabol.2014.10.030. Epub 2014 Oct 31.
10
Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
Brain. 2009 Feb;132(Pt 2):309-18. doi: 10.1093/brain/awn322. Epub 2008 Dec 2.
引用本文的文献
1
Long-term administration of morphine specifically alters the level of protein expression in different brain regions and affects the redox state.
Open Life Sci. 2024 Apr 20;19(1):20220858. doi: 10.1515/biol-2022-0858. eCollection 2024.
2
The multifaceted functions of β-arrestins and their therapeutic potential in neurodegenerative diseases.
Exp Mol Med. 2024 Feb;56(1):129-141. doi: 10.1038/s12276-023-01144-4. Epub 2024 Jan 11.
3
An efficient method to access spiro pseudoindoxyl ketones: evaluation of indoxyl and their -benzylated derivatives for inhibition of the activity of monoamine oxidases.
RSC Adv. 2023 Aug 22;13(36):24925-24935. doi: 10.1039/d3ra03641c. eCollection 2023 Aug 21.
4
Neuromodulation in Parkinson's disease targeting opioid and cannabinoid receptors, understanding the role of NLRP3 pathway: a novel therapeutic approach.
Inflammopharmacology. 2023 Aug;31(4):1605-1627. doi: 10.1007/s10787-023-01259-0. Epub 2023 Jun 15.
5
Deep brain stimulation (DBS) as a therapeutic approach in gait disorders: What does it bring to the table?
IBRO Neurosci Rep. 2023 May 19;14:507-513. doi: 10.1016/j.ibneur.2023.05.008. eCollection 2023 Jun.
6
δ-opioid Receptor, Microglia and Neuroinflammation.
Aging Dis. 2023 Jun 1;14(3):778-793. doi: 10.14336/AD.2022.0912.
7
-Opioid Receptor Activation Inhibits Ferroptosis by Activating the Nrf2 Pathway in MPTP-Induced Parkinson Disease Models.
Evid Based Complement Alternat Med. 2023 Feb 10;2023:4130937. doi: 10.1155/2023/4130937. eCollection 2023.
8
Hypoxic stress accelerates the propagation of pathological alpha-synuclein and degeneration of dopaminergic neurons.
CNS Neurosci Ther. 2023 Feb;29(2):544-558. doi: 10.1111/cns.14055. Epub 2022 Dec 13.
9
A Critical Role of δ-Opioid Receptor in Anti-microglial Activation Under Stress.
Front Aging Neurosci. 2022 May 19;14:847386. doi: 10.3389/fnagi.2022.847386. eCollection 2022.
10
Delta Opioid Receptor Activation with Delta Opioid Peptide [d-Ala2, d-Leu5] Enkephalin Contributes to Synaptic Improvement in Rat Hippocampus against Global Ischemia.
Cell Transplant. 2021 Jan-Dec;30:9636897211041585. doi: 10.1177/09636897211041585.
本文引用的文献
1
Simultaneous Transplantation of Fetal Ventral Mesencephalic Tissue and Encapsulated Genetically Modified Cells Releasing GDNF in a Hemi-Parkinsonian Rat Model of Parkinson's Disease.
Cell Transplant. 2017 Sep;26(9):1572-1581. doi: 10.1177/0963689717721202.
2
Hepcidin Protects Neuron from Hemin-Mediated Injury by Reducing Iron.
Front Physiol. 2017 May 23;8:332. doi: 10.3389/fphys.2017.00332. eCollection 2017.
3
Neuroprotective Effects and Mechanisms of Action of Multifunctional Agents Targeting Free Radicals, Monoamine Oxidase B and Cholinesterase in Parkinson's Disease Model.
J Mol Neurosci. 2017 Apr;61(4):498-510. doi: 10.1007/s12031-017-0891-3. Epub 2017 Jan 31.
4
Gene Therapy: A Promising Approach for Neuroprotection in Parkinson's Disease?
Front Neuroanat. 2016 Dec 20;10:123. doi: 10.3389/fnana.2016.00123. eCollection 2016.
5
The efficacy of Dynorphin fragments at the κ, μ and δ opioid receptor in transfected HEK cells and in an animal model of unilateral peripheral inflammation.
Peptides. 2017 Mar;89:9-16. doi: 10.1016/j.peptides.2016.12.019. Epub 2016 Dec 31.
6
Oxidative Stress, Pro-Inflammatory Cytokines, and Antioxidants Regulate Expression Levels of MicroRNAs in Parkinson's Disease.
Curr Aging Sci. 2017;10(3):177-184. doi: 10.2174/1874609810666170102144233.
7
Determinants of denervation-independent depletion of putamen dopamine in Parkinson's disease and multiple system atrophy.
Parkinsonism Relat Disord. 2017 Feb;35:88-91. doi: 10.1016/j.parkreldis.2016.12.011. Epub 2016 Dec 15.
8
Subcellular Parkinson's Disease-Specific Alpha-Synuclein Species Show Altered Behavior in Neurodegeneration.
Mol Neurobiol. 2017 Dec;54(10):7639-7655. doi: 10.1007/s12035-016-0266-8. Epub 2016 Nov 11.
9
The effects and mechanism of estrogen on rats with Parkinson's disease in different age groups.
Am J Transl Res. 2016 Oct 15;8(10):4134-4146. eCollection 2016.
10
Biobehavioral Framework of Symptom and Health Outcomes of Uncertainty and Psychological Stress in Parkinson Disease.
J Neurosci Nurs. 2016 Dec;48(6):E2-E9. doi: 10.1097/JNN.0000000000000244.
Zotero 插件